BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a virtual ...
Company recently filed an IND application for GDA-201; FDA placed the application on Clinical Hold pending modifications to donor eligibility procedures and sterility assay qualification Today’s ...
- On track for full BLA submission of omidubicel in the second quarter of 2022 - -Planning to open sites for enrollment in second quarter of 2022 for Phase 1/2 study of GDA-201 in patients with ...
Data from patients with NHL treated in Phase 1 investigator-led study of GDA-201 demonstrates median duration of response of 16 months; safety outcomes consistent after two years Poster presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results